1. Home
  2. LENZ vs CMPX Comparison

LENZ vs CMPX Comparison

Compare LENZ & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LENZ Therapeutics Inc.

LENZ

LENZ Therapeutics Inc.

HOLD

Current Price

$17.35

Market Cap

852.0M

Sector

Health Care

ML Signal

HOLD

Logo Compass Therapeutics Inc.

CMPX

Compass Therapeutics Inc.

HOLD

Current Price

$5.10

Market Cap

752.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LENZ
CMPX
Founded
2019
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
852.0M
752.4M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
LENZ
CMPX
Price
$17.35
$5.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$56.25
$13.44
AVG Volume (30 Days)
1.1M
1.9M
Earning Date
11-05-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,500,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$204.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$15.70
$1.33
52 Week High
$50.40
$5.86

Technical Indicators

Market Signals
Indicator
LENZ
CMPX
Relative Strength Index (RSI) 23.37 52.58
Support Level $15.70 $5.09
Resistance Level $29.02 $5.44
Average True Range (ATR) 2.37 0.34
MACD -0.91 -0.06
Stochastic Oscillator 9.76 32.30

Price Performance

Historical Comparison
LENZ
CMPX

About LENZ LENZ Therapeutics Inc.

LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.

About CMPX Compass Therapeutics Inc.

Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.

Share on Social Networks: